L Ouldamer1,2, S Bendifallah3,4, G Body5,6, G Canlorbe3,7, C Touboul8, O Graesslin9, E Raimond9, P Collinet10, C Coutant11, V Lavoué12, J Lévêque12, E Daraï3,7, M Ballester3,7. 1. Department of Gynecology, Centre Hospitalier Universitaire de Tours, Tours, France. l.ouldamer@chu-tours.fr. 2. INSERM U1069, Université François-Rabelais, Tours, France. l.ouldamer@chu-tours.fr. 3. Department of Obstetrics and Gynaecology, Hôpital Tenon, Assistance Publique des Hôpitaux de Paris, GRC-6 UPMC, Université Pierre et Marie Curie, Paris, France. 4. UMR S 707, Epidemiology, Information Systems, Modeling, Université Pierre et Marie Curie, Paris, France. 5. Department of Gynecology, Centre Hospitalier Universitaire de Tours, Tours, France. 6. INSERM U1069, Université François-Rabelais, Tours, France. 7. INSERM UMR S 938, Université Pierre et Marie Curie, Paris, France. 8. Department of Obstetrics and Gynaecology, Centre Hospitalier Intercommunal, Créteil, France. 9. Department of Obstetrics and Gynaecology, Institute Alix de Champagne University Hospital, Reims, France. 10. Department of Gynecological Surgery, Jeanne de Flandre University Hospital, Lille, France. 11. Centre de lutte contre le cancer Georges François Leclerc, Dijoin, France. 12. Departement of Gynecological Surgery, Rennes University Hospital, Rennes, France.
Abstract
BACKGROUND: The European Society of Medical Oncology (ESMO)/European Society of Gynaecological Oncology (ESGO)/European Society for Radiotherapy & Oncology (ESTRO) classification for endometrial cancer (EC) now includes a high-intermediate risk (HIR) group of recurrence due to the adverse prognostic role of lymphovascular space involvement (LVSI) and grade 3 for women at intermediate risk. However, optimal surgical staging, and especially the place of lymphadenectomy, remains to be elucidated. We aimed to establish whether systematic nodal staging should be part of surgical staging for women with HIR EC. METHODS: We abstracted from a prospectively maintained multicentre database the data of 181 women with HIR EC based on uterine factors (endometrioid type 1, grade 1-2 tumors with deep (≥50%) myometrial invasion and unequivocally positive LVSI, and those with grade 3 tumors with <50% myometrial invasion regardless of LVSI status), who received primary surgical treatment between January 2001 and December 2013. We recorded frequency of lymph node (LN) metastases in those who underwent nodal staging. The secondary outcomes were overall survival and recurrence patterns. RESULTS: Overall, 145 (80.1%) women underwent nodal staging consisting of at least pelvic lymphadenectomy. Of these, 62 (42.7%) had LN disease (9.7% with micrometastases). The respective 5-year overall survival rates according to LN status were 85.0% (95% confidence interval [CI] 76.5-91.4), 71.8% (95% CI 61.9-80.4) and 36.0% (95% CI 26.6-46.2) for women with negative LN, positive LN, and unstaged (p = 0.047). Unstaged women were more likely to experience nodal recurrence than surgically staged/LN negative women (p = 0.05). CONCLUSIONS: Systematic nodal staging should be part of surgical staging for women with apparent ESMO/ESGO/ESTRO HIR EC. Sentinel LN biopsy (SLNB) could be an option in this specific setting that may possibly substitute comprehensive staging, for the identification of patients with lymphatic dissemination.
BACKGROUND: The European Society of Medical Oncology (ESMO)/European Society of Gynaecological Oncology (ESGO)/European Society for Radiotherapy & Oncology (ESTRO) classification for endometrial cancer (EC) now includes a high-intermediate risk (HIR) group of recurrence due to the adverse prognostic role of lymphovascular space involvement (LVSI) and grade 3 for women at intermediate risk. However, optimal surgical staging, and especially the place of lymphadenectomy, remains to be elucidated. We aimed to establish whether systematic nodal staging should be part of surgical staging for women with HIR EC. METHODS: We abstracted from a prospectively maintained multicentre database the data of 181 women with HIR EC based on uterine factors (endometrioid type 1, grade 1-2 tumors with deep (≥50%) myometrial invasion and unequivocally positive LVSI, and those with grade 3 tumors with <50% myometrial invasion regardless of LVSI status), who received primary surgical treatment between January 2001 and December 2013. We recorded frequency of lymph node (LN) metastases in those who underwent nodal staging. The secondary outcomes were overall survival and recurrence patterns. RESULTS: Overall, 145 (80.1%) women underwent nodal staging consisting of at least pelvic lymphadenectomy. Of these, 62 (42.7%) had LN disease (9.7% with micrometastases). The respective 5-year overall survival rates according to LN status were 85.0% (95% confidence interval [CI] 76.5-91.4), 71.8% (95% CI 61.9-80.4) and 36.0% (95% CI 26.6-46.2) for women with negative LN, positive LN, and unstaged (p = 0.047). Unstaged women were more likely to experience nodal recurrence than surgically staged/LN negative women (p = 0.05). CONCLUSIONS: Systematic nodal staging should be part of surgical staging for women with apparent ESMO/ESGO/ESTRO HIR EC. Sentinel LN biopsy (SLNB) could be an option in this specific setting that may possibly substitute comprehensive staging, for the identification of patients with lymphatic dissemination.
Authors: Maria Luisa Gasparri; Donatella Caserta; Pierluigi Benedetti Panici; Andrea Papadia; Michael D Mueller Journal: J Cancer Res Clin Oncol Date: 2018-11-20 Impact factor: 4.553
Authors: Katarzyna Holub; Fabio Busato; Sebastien Gouy; Roger Sun; Patricia Pautier; Catherine Genestie; Philippe Morice; Alexandra Leary; Eric Deutsch; Christine Haie-Meder; Albert Biete; Cyrus Chargari Journal: J Clin Med Date: 2020-05-12 Impact factor: 4.241
Authors: Elaine C Candido; Osmar F Rangel Neto; Maria Carolina S Toledo; José Carlos C Torres; Aurea A A Cairo; Joana F Braganca; Julio C Teixeira Journal: Eur J Obstet Gynecol Reprod Biol X Date: 2019-04-18
Authors: Sarah Brugger; Moritz Hamann; Marc Mosner; Michaela Beer; Michael Braun; Martin Pölcher Journal: World J Surg Oncol Date: 2018-05-17 Impact factor: 2.754
Authors: Luigi Della Corte; Pierluigi Giampaolino; Antonio Mercorio; Gaetano Riemma; Antonio Schiattarella; Pasquale De Franciscis; Giuseppe Bifulco Journal: Transl Cancer Res Date: 2020-12 Impact factor: 1.241